BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forneris F, Wu J, Xue X, Ricklin D, Lin Z, Sfyroera G, Tzekou A, Volokhina E, Granneman JC, Hauhart R, Bertram P, Liszewski MK, Atkinson JP, Lambris JD, Gros P. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J 2016;35:1133-49. [PMID: 27013439 DOI: 10.15252/embj.201593673] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 López-Perrote A, Harrison RE, Subías M, Alcorlo M, Rodríguez de Córdoba S, Morikis D, Llorca O. Ionic tethering contributes to the conformational stability and function of complement C3b. Mol Immunol 2017;85:137-47. [PMID: 28254726 DOI: 10.1016/j.molimm.2016.12.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Pedersen H, Jensen RK, Hansen AG, Gadeberg TAF, Thiel S, Laursen NS, Andersen GR. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. J Biol Chem 2020;295:8746-58. [PMID: 32376685 DOI: 10.1074/jbc.RA119.012339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Saleem M, Shaikh S, Hu Z, Pozzi N, Java A. Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature. Front Immunol 2022;13:909503. [PMID: 35720299 DOI: 10.3389/fimmu.2022.909503] [Reference Citation Analysis]
4 Omoyinmi E, Mohamoud I, Gilmour K, Brogan PA, Eleftheriou D. Cutaneous Vasculitis and Digital Ischaemia Caused by Heterozygous Gain-of-Function Mutation in C3. Front Immunol 2018;9:2524. [PMID: 30443255 DOI: 10.3389/fimmu.2018.02524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Qiu WQ, Luo S, Ma SA, Saminathan P, Li H, Gunnersen JM, Gelbard HA, Hammond JW. The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases. Front Immunol 2021;12:607641. [PMID: 33936031 DOI: 10.3389/fimmu.2021.607641] [Reference Citation Analysis]
6 Pedersen DV, Roumenina L, Jensen RK, Gadeberg TA, Marinozzi C, Picard C, Rybkine T, Thiel S, Sørensen UB, Stover C, Fremeaux-Bacchi V, Andersen GR. Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO J 2017;36:1084-99. [PMID: 28264884 DOI: 10.15252/embj.201696173] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
7 Fang S, Wang H, Lu L, Jia Y, Xia Z. Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study. Int Immunopharmacol 2020;89:107070. [PMID: 33039965 DOI: 10.1016/j.intimp.2020.107070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
8 Fernández FJ, Gómez S, Vega MC. Pathogens' toolbox to manipulate human complement. Semin Cell Dev Biol 2019;85:98-109. [PMID: 29221973 DOI: 10.1016/j.semcdb.2017.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Atkinson JP, Du Clos TW, Mold C, Kulkarni H, Hourcade D, Wu X. The Human Complement System. Clinical Immunology. Elsevier; 2019. pp. 299-317.e1. [DOI: 10.1016/b978-0-7020-6896-6.00021-1] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
10 Peoples N, Strang C. Complement Activation in the Central Nervous System: A Biophysical Model for Immune Dysregulation in the Disease State. Front Mol Neurosci 2021;14:620090. [PMID: 33746710 DOI: 10.3389/fnmol.2021.620090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zewde N, Mohan RR, Morikis D. Immunophysical Evaluation of the Initiating Step in the Formation of the Membrane Attack Complex. Front Phys 2018;6:130. [DOI: 10.3389/fphy.2018.00130] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Kumar J, Yadav VN, Phulera S, Kamble A, Gautam AK, Panwar HS, Sahu A. Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I. J Virol 2017;91:e00668-17. [PMID: 28724763 DOI: 10.1128/JVI.00668-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Maloney BE, Perera KD, Saunders DRD, Shadipeni N, Fleming SD. Interactions of viruses and the humoral innate immune response. Clin Immunol 2020;212:108351. [PMID: 32028020 DOI: 10.1016/j.clim.2020.108351] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 de Jorge EG, Yebenes H, Serna M, Tortajada A, Llorca O, de Córdoba SR. How novel structures inform understanding of complement function. Semin Immunopathol 2018;40:3-14. [PMID: 28808775 DOI: 10.1007/s00281-017-0643-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ojha H, Ghosh P, Singh Panwar H, Shende R, Gondane A, Mande SC, Sahu A. Spatially conserved motifs in complement control protein domains determine functionality in regulators of complement activation-family proteins. Commun Biol 2019;2:290. [PMID: 31396570 DOI: 10.1038/s42003-019-0529-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
16 Sharp TH, Boyle AL, Diebolder CA, Kros A, Koster AJ, Gros P. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b. Proc Natl Acad Sci U S A 2019;116:11900-5. [PMID: 31147461 DOI: 10.1073/pnas.1901841116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
17 Walter L, Sürth V, Röttgerding F, Zipfel PF, Fritz-Wolf K, Kraiczy P. Elucidating the Immune Evasion Mechanisms of Borrelia mayonii, the Causative Agent of Lyme Disease. Front Immunol 2019;10:2722. [PMID: 31849943 DOI: 10.3389/fimmu.2019.02722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
18 Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation 2020;17:354. [PMID: 33239010 DOI: 10.1186/s12974-020-02024-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
19 Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest 2016;126:4640-53. [PMID: 27841764 DOI: 10.1172/JCI85856] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
20 Papanastasiou M, Koutsogiannaki S, Sarigiannis Y, Geisbrecht BV, Ricklin D, Lambris JD. Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. J Immunol 2017;198:3326-35. [PMID: 28258193 DOI: 10.4049/jimmunol.1601864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
21 Łukawska E, Polcyn-adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med 2018;18:297-318. [DOI: 10.1007/s10238-018-0491-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
22 Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight 2018;3:121497. [PMID: 30185663 DOI: 10.1172/jci.insight.121497] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
23 Ruben E, Planer W, Chinnaraj M, Chen Z, Zuo X, Pengo V, De Filippis V, Alluri RK, McCrae KR, Macor P, Tedesco F, Pozzi N. The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. J Biol Chem 2020;295:10794-806. [PMID: 32518155 DOI: 10.1074/jbc.RA120.013939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
24 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
25 Geerlings MJ, Volokhina EB, de Jong EK, van de Kar N, Pauper M, Hoyng CB, van den Heuvel LP, den Hollander AI. Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration. Clin Genet 2018;94:330-8. [PMID: 29888403 DOI: 10.1111/cge.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
26 Park DH, Connor KM, Lambris JD. The Challenges and Promise of Complement Therapeutics for Ocular Diseases. Front Immunol 2019;10:1007. [PMID: 31156618 DOI: 10.3389/fimmu.2019.01007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
27 Merle NS, Boudhabhay I, Leon J, Fremeaux-Bacchi V, Roumenina LT. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Transfus Clin Biol 2019;26:116-24. [PMID: 30879901 DOI: 10.1016/j.tracli.2019.02.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
28 Pigoni M, Hsia HE, Hartmann J, Rudan Njavro J, Shmueli MD, Müller SA, Güner G, Tüshaus J, Kuhn PH, Kumar R, Gao P, Tran ML, Ramazanov B, Blank B, Hipgrave Ederveen AL, Von Blume J, Mulle C, Gunnersen JM, Wuhrer M, Rammes G, Busche MA, Koeglsperger T, Lichtenthaler SF. Seizure protein 6 controls glycosylation and trafficking of kainate receptor subunits GluK2 and GluK3. EMBO J 2020;39:e103457. [PMID: 32567721 DOI: 10.15252/embj.2019103457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
29 Agrawal P, Sharma S, Pal P, Ojha H, Mullick J, Sahu A. The imitation game: a viral strategy to subvert the complement system. FEBS Lett 2020;594:2518-42. [DOI: 10.1002/1873-3468.13856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Narkhede YB, Gautam AK, Hsu RV, Rodriguez W, Zewde NT, Harrison RES, Arantes PR, Gaieb Z, Gorham RD Jr, Kieslich C, Morikis D, Sahu A, Palermo G. Role of Electrostatic Hotspots in the Selectivity of Complement Control Proteins Toward Human and Bovine Complement Inhibition. Front Mol Biosci 2021;8:618068. [PMID: 33829039 DOI: 10.3389/fmolb.2021.618068] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zwarthoff SA, Berends ETM, Mol S, Ruyken M, Aerts PC, Józsi M, de Haas CJC, Rooijakkers SHM, Gorham RD Jr. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models. Front Immunol 2018;9:1691. [PMID: 30083158 DOI: 10.3389/fimmu.2018.01691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
32 Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J Control Release 2019;302:181-9. [PMID: 30974134 DOI: 10.1016/j.jconrel.2019.04.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
33 Pedersen DV, Gadeberg TAF, Thomas C, Wang Y, Joram N, Jensen RK, Mazarakis SMM, Revel M, El Sissy C, Petersen SV, Lindorff-Larsen K, Thiel S, Laursen NS, Fremeaux-Bacchi V, Andersen GR. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front Immunol 2019;10:2007. [PMID: 31507604 DOI: 10.3389/fimmu.2019.02007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
34 Michels MAHM, van de Kar NCAJ, Volokhina EB, van den Heuvel BPWJ. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity. In: Roumenina LT, editor. The Complement System. New York: Springer US; 2021. pp. 83-96. [DOI: 10.1007/978-1-0716-1016-9_8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat Struct Mol Biol 2017;24:643-51. [PMID: 28671664 DOI: 10.1038/nsmb.3427] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
36 Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM. HSP70 Multi-Functionality in Cancer. Cells 2020;9:E587. [PMID: 32121660 DOI: 10.3390/cells9030587] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
37 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
38 Vasilev VV, Radanova M, Lazarov VJ, Dragon-Durey MA, Fremeaux-Bacchi V, Roumenina LT. Autoantibodies Against C3b-Functional Consequences and Disease Relevance. Front Immunol 2019;10:64. [PMID: 30761135 DOI: 10.3389/fimmu.2019.00064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
39 Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD. Novel mechanisms and functions of complement. Nat Immunol 2017;18:1288-98. [PMID: 29144501 DOI: 10.1038/ni.3858] [Cited by in Crossref: 200] [Cited by in F6Publishing: 192] [Article Influence: 40.0] [Reference Citation Analysis]
40 van den Bos RM, Pearce NM, Granneman J, Brondijk THC, Gros P. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b. Front Immunol 2019;10:2097. [PMID: 31552043 DOI: 10.3389/fimmu.2019.02097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
41 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
42 Fung KW, Wright DW, Gor J, Swann MJ, Perkins SJ. Domain structure of human complement C4b extends with increasing NaCl concentration: implications for its regulatory mechanism. Biochem J 2016;473:4473-91. [PMID: 27738201 DOI: 10.1042/BCJ20160744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Java A, Pozzi N, Love-Gregory LD, Heusel JW, Sung YJ, Hu Z, Bertram P, Liszewski MK, Cline LM, Ren Z, Atkinson JP. A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic Syndrome. Kidney Int Rep 2019;4:1007-17. [PMID: 31312772 DOI: 10.1016/j.ekir.2019.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Panwar HS, Ojha H, Ghosh P, Barage SH, Raut S, Sahu A. Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins. Proc Natl Acad Sci U S A 2019;116:9953-8. [PMID: 31036650 DOI: 10.1073/pnas.1818573116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Wahid AA, Dunphy RW, Macpherson A, Gibson BG, Kulik L, Whale K, Back C, Hallam TM, Alkhawaja B, Martin RL, Meschede I, Laabei M, Lawson ADG, Holers VM, Watts AG, Crennell SJ, Harris CL, Marchbank KJ, van den Elsen JMH. Insights Into the Structure-Function Relationships of Dimeric C3d Fragments. Front Immunol 2021;12:714055. [PMID: 34434196 DOI: 10.3389/fimmu.2021.714055] [Reference Citation Analysis]
46 Ong-Pålsson E, Njavro JR, Wilson Y, Pigoni M, Schmidt A, Müller SA, Meyer M, Hartmann J, Busche MA, Gunnersen JM, Munro KM, Lichtenthaler SF. The β-Secretase Substrate Seizure 6-Like Protein (SEZ6L) Controls Motor Functions in Mice. Mol Neurobiol 2021. [PMID: 34958451 DOI: 10.1007/s12035-021-02660-y] [Reference Citation Analysis]
47 Hart K, Harvey M, Tang M, Wu Z, Cave G. Liposomes to Augment Dialysis in Preclinical Models: A Structured Review. Pharmaceutics 2021;13:395. [PMID: 33809774 DOI: 10.3390/pharmaceutics13030395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Jacquet M, Cioci G, Fouet G, Bally I, Thielens NM, Gaboriaud C, Rossi V. C1q and Mannose-Binding Lectin Interact with CR1 in the Same Region on CCP24-25 Modules. Front Immunol 2018;9:453. [PMID: 29563915 DOI: 10.3389/fimmu.2018.00453] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
49 Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev 2016;274:33-58. [PMID: 27782325 DOI: 10.1111/imr.12500] [Cited by in Crossref: 139] [Cited by in F6Publishing: 130] [Article Influence: 27.8] [Reference Citation Analysis]
50 Gaikwad H, Li Y, Gifford G, Groman E, Banda NK, Saba L, Scheinman R, Wang G, Simberg D. Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood. Bioconjug Chem 2020;31:1844-56. [PMID: 32598839 DOI: 10.1021/acs.bioconjchem.0c00342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Li J, Long D, Wu S, Wu X, Wei B, Chen D, Shao Y, Wang H, Cui L, Chen X, Yu L. Association of CFH polymorphism with susceptibility to sepsis caused by Pseudomonas aeruginosa in Chinese Han populations: A multi-center study. Gene 2020;722:144127. [PMID: 31525397 DOI: 10.1016/j.gene.2019.144127] [Reference Citation Analysis]
52 Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. Immunol Rev 2016;274:152-71. [PMID: 27782321 DOI: 10.1111/imr.12475] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 19.8] [Reference Citation Analysis]
53 Joosten RP, Lütteke T. Carbohydrate 3D structure validation. Curr Opin Struct Biol 2017;44:9-17. [PMID: 27816840 DOI: 10.1016/j.sbi.2016.10.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
54 Forneris F, Wu J, Xue X, Ricklin D, Lin Z, Sfyroera G, Tzekou A, Volokhina E, Granneman JC, Hauhart R, Bertram P, Liszewski MK, Atkinson JP, Lambris JD, Gros P. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J 2016;35:1133-49. [PMID: 27013439 DOI: 10.15252/embj.201593673] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
55 Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, Kirschfink M, Hovius JW, Zipfel PF, Wallich R, Kraiczy P. Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties. Sci Rep 2017;7:303. [PMID: 28331202 DOI: 10.1038/s41598-017-00412-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
56 Wang L, Gong T, Brown Z, Randle C, Guan Y, Ye W, Ming W. Ascidian-Inspired Heparin-Mimetic Magnetic Nanoparticles with Potential for Application in Hemodialysis as Recycling Anticoagulants. ACS Biomater Sci Eng 2020;6:1998-2006. [PMID: 33455351 DOI: 10.1021/acsbiomaterials.9b01865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. J Immunol Res 2021;2021:9945725. [PMID: 34368372 DOI: 10.1155/2021/9945725] [Reference Citation Analysis]
58 Jensen RK, Pihl R, Gadeberg TAF, Jensen JK, Andersen KR, Thiel S, Laursen NS, Andersen GR. A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. J Biol Chem 2018;293:6269-81. [PMID: 29497000 DOI: 10.1074/jbc.RA117.001179] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
59 Kumar S, Chinnaraj M, Planer W, Zuo X, Macor P, Tedesco F, Pozzi N. An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. J Biol Chem 2021;297:100890. [PMID: 34197876 DOI: 10.1016/j.jbc.2021.100890] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]